Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Regeneron Pharmaceuticals Inc (REGN)  
$1,024.09 20.57 (1.97%) as of 4:30 Wed 7/3


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 104,690,000
Market Cap: 107.21(B)
Last Volume: 378,341 Avg Vol: 759,306
52 Week Range: $692.45 - $1071.19
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     S&P SMALLCAP 600
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  150
Guru Rank Value     : 6.9
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 191,758 236,826 311,409 468,643
Total Sell Value $188,359,854 $231,314,072 $294,701,490 $404,818,815
Total People Sold 7 13 16 18
Total Sell Transactions 16 39 65 127
End Date 2024-04-04 2024-01-02 2023-07-04 2022-07-04

   
Records found: 2433
  Page 63 of 98  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Goldberg Murray A SVP Finance and Admin CFO and   •       –      –    2013-05-20 4 D $266.64 $21,633,036 D/D (81,132) 125,427     -
   Goldberg Murray A SVP Finance and Admin CFO and   •       –      –    2013-05-20 4 OE $16.80 $2,962,169 D/D 147,967 135,803     -
   Brown Michael S Director   –       •      –    2013-05-17 4 S $269.00 $1,345,120 D/D (5,000) 14,662     -
   Brown Michael S Director   –       •      –    2013-05-15 4 S $278.28 $2,782,800 D/D (10,000) 19,662     -
   Brown Michael S Director   –       •      –    2013-05-15 4 OE $24.41 $366,150 D/D 15,000 29,662     -
   Aberman Michael S VP Strategy and Investor Relat   •       –      –    2013-05-14 4 AS $278.72 $1,545,960 D/D (5,529) 11,700     -
   Aberman Michael S VP Strategy and Investor Relat   •       –      –    2013-05-13 4 D $275.97 $1,923,787 D/D (6,971) 17,229     -
   Aberman Michael S VP Strategy and Investor Relat   •       –      –    2013-05-13 4 OE $24.00 $300,000 D/D 12,500 24,200     -
   Stahl Neil SVP Research and Development S   •       –      –    2013-05-13 4 S $276.71 $6,378,806 D/D (23,038) 48,988     -
   Stahl Neil SVP Research and Development S   •       –      –    2013-05-10 4 D $268.40 $8,696,160 D/D (32,400) 72,026     -
   Stahl Neil SVP Research and Development S   •       –      –    2013-05-10 4 OE $21.92 $1,215,201 D/D 55,438 104,426     -
   Sing George L Director   –       •      –    2013-05-10 4 S $270.00 $1,350,000 D/D (5,000) 112,772     -
   Sing George L Director   –       •      –    2013-05-10 4 OE $15.01 $75,050 D/D 5,000 117,772     -
   Terifay Robert J SVP Commercial   •       –      –    2013-05-08 4 S $260.86 $2,150,192 D/D (8,231) 15,324     -
   Terifay Robert J SVP Commercial   •       –      –    2013-05-07 4 D $261.67 $2,274,436 D/D (8,692) 23,555     -
   Terifay Robert J SVP Commercial   •       –      –    2013-05-07 4 OE $16.80 $284,306 D/D 16,923 24,444     -
   Van Plew Daniel P SVP & General Mgr Industrial O   •       –      –    2013-05-07 4 S $260.88 $3,590,637 D/D (13,725) 10,736     -
   Yancopoulos George President Regeneron Laboratori   •       •      –    2013-05-07 4 S $261.66 $26,263,581 D/D (100,000) 1,106,395     -
   Vagelos P Roy Chairman of the Board   •       •      –    2013-05-06 4/A S $263.15 $3,162,537 I/I (12,018) 114,750     -
   Aberman Michael S VP Strategy and Investor Relat   •       –      –    2013-05-06 4 S $256.46 $2,142,927 D/D (8,334) 11,700     -
   Aberman Michael S VP Strategy and Investor Relat   •       –      –    2013-05-06 4 OE $24.00 $200,016 D/D 8,334 13,300     -
   Tessier-Lavigne Marc Director   –       •      –    2013-05-06 4 S $260.20 $3,478,942 D/D (13,334) 0     -
   Tessier-Lavigne Marc Director   –       •      –    2013-05-06 4 OE $50.91 $709,834 D/D 13,334 300     -
   Gilman Alfred G Director   –       •      –    2013-05-06 4 S $260.41 $7,831,302 D/D (30,000) 0     -
   Gilman Alfred G Director   –       •      –    2013-05-06 4 OE $19.69 $652,950 D/D 30,000 9,600     -
  2433 Records found
  Previous  60  61  62  63  64  65  66  67  68  69  Next   
  Page 63 of 98
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us